VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a technical milestone in the detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples, supporting early detection of immune disruptions associated with conditions like sepsis across point-of-care and non-laboratory settings.
The company noted that the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. This approach could expand access to testing through point-of-care use and broaden Volition's addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Early detection is critical for improving outcomes, but traditional testing often requires laboratory equipment and trained personnel. Volition's finger-prick prototype aims to make testing more accessible, particularly in resource-limited settings.
The milestone is part of the SUMMIT program, which focuses on developing simple, cost-effective blood tests for diseases associated with NETosis, such as sepsis. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more details, view the full press release at https://ibn.fm/ioEmu.
